In the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) clinical trial and the Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6) clinical trial, treatment with liraglutide or semaglutide compared with placebo resulted in fewer patients experiencing a composite cardiovascular outcome and decreased risk of CKD development and progressionbenefits mainly driven by the reduction in new-onset macroalbuminuria (2, 3, 5)
COMPLETE AND PREMIUM FORMULA: Enriched with vitamin C, hyaluronic acid, alpha-lipoic acid and phosphatidylcholine
This article examines the evidence, mechanisms, symptoms, and management strategies for gallbladder issues related to GLP-1 therapy
Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al